Enzalutamide + ADT in Men with De Novo mHSPC: The ARCHES Trial

Enzalutamide + ADT in Men with De Novo mHSPC: The ARCHES Trial

ARCHES: OS by high or low disease volume and progression to mHSPC or de novo mHSPCПодробнее

ARCHES: OS by high or low disease volume and progression to mHSPC or de novo mHSPC

ARCHES trial: androgen deprivation therapy with enzalutamide or placebo in mHSPCПодробнее

ARCHES trial: androgen deprivation therapy with enzalutamide or placebo in mHSPC

Enzalutamide plus androgen deprivation therapy prolongs survival in men with metastatic hormone-...Подробнее

Enzalutamide plus androgen deprivation therapy prolongs survival in men with metastatic hormone-...

New Approaches to Metastatic Hormone Sensitive Prostate CancerПодробнее

New Approaches to Metastatic Hormone Sensitive Prostate Cancer

ARCHES trialПодробнее

ARCHES trial

ARCHES: enzalutamide plus ADT in mHSPC subgroupsПодробнее

ARCHES: enzalutamide plus ADT in mHSPC subgroups

ARCHES trial overview: ADT plus enzalutamide for metastatic hormone-sensitive prostate cancerПодробнее

ARCHES trial overview: ADT plus enzalutamide for metastatic hormone-sensitive prostate cancer

ARCHES trial: enzalutamide plus ADT for mHSPCПодробнее

ARCHES trial: enzalutamide plus ADT for mHSPC

Update on the ARCHES Trial: New Indication for Enzalutamide in mHSPCПодробнее

Update on the ARCHES Trial: New Indication for Enzalutamide in mHSPC

ARCHES: OS in mHSPC who recieved prior ADT and reached low PSA further treated with enzalutamideПодробнее

ARCHES: OS in mHSPC who recieved prior ADT and reached low PSA further treated with enzalutamide

Update on overall survival in ARCHES trialПодробнее

Update on overall survival in ARCHES trial

STREAM trial: enzalutamide and androgen deprivation therapy with salvage radiation in men with h...Подробнее

STREAM trial: enzalutamide and androgen deprivation therapy with salvage radiation in men with h...

ARCHES post-hoc analyses: efficacy of ENZA + ADT in mHSPC by pattern of metastatic spreadПодробнее

ARCHES post-hoc analyses: efficacy of ENZA + ADT in mHSPC by pattern of metastatic spread

Dr. Stenzl on the Safety Profile of Enzalutamide/ADT in mHSPCПодробнее

Dr. Stenzl on the Safety Profile of Enzalutamide/ADT in mHSPC

Update on ARCHES trial: implications for prostate cancer treatmentПодробнее

Update on ARCHES trial: implications for prostate cancer treatment

ENZAMET & ARCHES Trials Provides Evidence of Enzalutamide as Life Prolonging Therapy in mHSPCПодробнее

ENZAMET & ARCHES Trials Provides Evidence of Enzalutamide as Life Prolonging Therapy in mHSPC

Enzalutamide as treatment for men with mHSPC who have received testosterone suppressionПодробнее

Enzalutamide as treatment for men with mHSPC who have received testosterone suppression

Final OS analysis from ARCHESПодробнее

Final OS analysis from ARCHES

ARCHES: radiographic progression in the absence of PSA progression in patients with mHSPCПодробнее

ARCHES: radiographic progression in the absence of PSA progression in patients with mHSPC

Updated overall survival outcomes in ENZAMET (ANZUP 1304)Подробнее

Updated overall survival outcomes in ENZAMET (ANZUP 1304)